Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OLMA | Olema Pharmaceuticals, Inc.

IndexRUT P/E- EPS (ttm)-2.41 Insider Own1.10% Shs Outstand40.72M Perf Week-0.99%
Market Cap468.93M Forward P/E- EPS next Y-2.33 Insider Trans332.56% Shs Float25.37M Perf Month26.50%
Income-97.30M PEG- EPS next Q-0.49 Inst Own84.60% Short Float / Ratio6.25% / 4.44 Perf Quarter44.59%
Sales- P/S- EPS this Y-45.70% Inst Trans-2.62% Short Interest1.59M Perf Half Y252.79%
Book/sh3.97 P/B3.03 EPS next Y-1.80% ROA-47.40% Target Price21.43 Perf Year274.77%
Cash/sh4.30 P/C2.80 EPS next 5Y- ROE-51.80% 52W Range2.19 - 13.50 Perf YTD391.02%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-10.89% Beta2.58
Dividend %- Quick Ratio11.60 Sales past 5Y- Gross Margin- 52W Low449.32% ATR0.90
Employees67 Current Ratio11.60 Sales Q/Q- Oper. Margin- RSI (14)57.67 Volatility6.73% 8.53%
OptionableYes Debt/Eq0.00 EPS Q/Q40.00% Profit Margin- Rel Volume0.50 Prev Close12.09
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume357.41K Price12.03
Recom1.70 SMA207.39% SMA5020.10% SMA20095.49% Volume179,963 Change-0.50%
Date Action Analyst Rating Change Price Target Change
Jul-21-23Initiated Oppenheimer Outperform $21
May-05-23Initiated CapitalOne Overweight $16
Feb-22-23Initiated Credit Suisse Outperform $12
Jul-06-22Resumed Canaccord Genuity Buy $16
Jun-09-22Upgrade H.C. Wainwright Neutral → Buy $12
Feb-28-22Initiated H.C. Wainwright Neutral
Dec-07-21Resumed Cowen Outperform
Dec-14-20Initiated JP Morgan Overweight $52
Dec-14-20Initiated Jefferies Buy $70
Dec-14-20Initiated Cowen Outperform
Dec-14-20Initiated Canaccord Genuity Buy $60
Sep-20-23 07:29AM
Sep-15-23 01:09PM
Sep-14-23 11:02PM
Sep-08-23 12:00PM
04:02PM Loading…
Sep-07-23 04:02PM
Sep-06-23 04:30PM
Sep-05-23 04:30PM
Aug-08-23 04:03PM
Aug-02-23 04:30PM
Aug-01-23 08:00AM
Jul-05-23 07:30AM
Jun-14-23 01:00PM
04:30PM Loading…
Jun-02-23 04:30PM
May-30-23 04:30PM
May-19-23 06:29AM
May-11-23 08:43AM
May-09-23 04:01PM
May-08-23 07:06AM
May-02-23 04:30PM
Apr-13-23 04:30PM
Apr-04-23 04:30PM
Mar-09-23 04:00PM
Mar-02-23 05:00PM
Feb-21-23 04:30PM
Feb-02-23 06:00PM
Jan-04-23 04:30PM
07:00AM Loading…
Jan-03-23 07:00AM
Jan-02-23 08:23AM
Dec-07-22 03:37PM
Dec-02-22 04:30PM
Nov-21-22 09:16AM
Nov-08-22 04:30PM
Nov-02-22 04:30PM
Nov-01-22 08:00AM
Oct-26-22 08:01AM
Oct-12-22 07:01AM
Oct-04-22 04:29PM
Sep-06-22 04:30PM
Sep-01-22 05:01PM
Aug-09-22 04:35PM
Aug-04-22 04:30PM
Aug-03-22 04:30PM
Jul-26-22 07:32AM
Jul-22-22 06:49AM
Jul-21-22 07:30AM
Jul-07-22 10:40AM
Jul-05-22 04:30PM
Jun-09-22 07:35AM
Jun-02-22 04:30PM
May-24-22 04:30PM
May-09-22 04:30PM
May-03-22 04:30PM
Apr-18-22 04:30PM
Apr-04-22 07:30AM
Mar-08-22 04:35PM
Feb-28-22 04:30PM
Feb-22-22 07:30AM
Feb-16-22 10:06AM
Feb-03-22 05:00PM
Jan-31-22 07:30AM
Jan-04-22 07:30AM
Dec-16-21 12:38PM
Dec-01-21 04:09PM
Nov-30-21 11:02AM
Nov-29-21 04:27PM
Nov-22-21 07:30AM
Nov-19-21 12:00PM
Nov-10-21 04:05PM
Nov-09-21 07:30AM
Oct-18-21 11:01AM
Oct-13-21 11:43AM
Sep-30-21 05:00PM
Sep-09-21 07:30AM
Aug-30-21 04:05PM
Aug-18-21 10:46AM
Aug-10-21 04:05PM
Jul-28-21 04:05PM
May-18-21 04:05PM
May-11-21 04:05PM
Apr-07-21 07:30AM
Apr-06-21 07:30AM
Mar-17-21 04:05PM
Mar-10-21 04:45PM
Feb-23-21 07:00AM
Feb-19-21 04:59AM
Dec-31-20 03:42PM
Dec-17-20 07:00AM
Dec-07-20 07:39AM
Dec-03-20 05:18PM
Nov-23-20 04:01PM
Nov-20-20 01:33PM
Nov-19-20 06:39PM
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSep 19Sale12.6720,000253,400572,011Sep 21 05:00 PM
BVF PARTNERS L P/ILDirectorSep 12Buy9.841,505,93214,818,3714,688,954Sep 14 04:25 PM
Harmon CyrusDirectorSep 05Sale11.6210,000116,200998,714Sep 05 09:08 PM
Harmon CyrusDirectorAug 31Sale9.3615,000140,4001,008,714Sep 05 09:08 PM
Harmon CyrusDirectorAug 16Sale10.1415,000152,1001,023,714Aug 17 05:00 PM
Harmon CyrusDirectorJun 08Sale6.3010,00063,0001,038,714Jun 09 05:30 PM
Harmon CyrusDirectorJun 06Sale6.295,00031,4751,048,714Jun 07 09:30 PM
Harmon CyrusDirectorJun 05Sale6.045,00030,2251,053,714Jun 07 09:30 PM